As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

It's impossible to avoid headlines about GLP-1 medications. The weight-loss drugs target hormones in the gut and brain that ...

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA versus those not on a GLP-1 RA.

ATLANTA -- Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.